CDMOs Axplora and Flamma have both made announcements about investments in flow chemistry, with the former completing the installation of a new cGMP pilot unit at Leverkusen, Germany, and the latter investing about $2 million in flow, starting with the installation of a new suite of equipment from Microinnova at Chignolo D’Isola, Italy.

Following negotiations begun in September 2021, PharmaZell, a German-based supplier of speciality APIs, and Novasep, a CDMO focused on complex small molecules and ADCs, have closed their merger under the majority ownership of Bridgepoint Group. Former PharmaZell CEO Dr Sylke Hassel (pictured) will be CEO, while former Novasep CEO Michel Spagnol has joined the board of directors.

PharmaZell, a German-based producer of speciality APIs, and France’s CDMO Groupe Novasep are to merge under the ownership of PharmaZell’s current majority shareholder, private equity firm Bridgepoint. This remains subject to consultation with employees and other closing conditions.